Use of proteomic patterns in serum to identify ovarian cancer

被引:2569
作者
Petricoin, EF
Ardekani, AM
Hitt, BA
Levine, PJ
Fusaro, VA
Steinberg, SM
Mills, GB
Simone, C
Fishman, DA
Kohn, EC
Liotta, LA
机构
[1] US FDA, Natl Inst Hlth Clin Proteom Program, Dept Therapeut Prot, Ctr Biol Evaluat & Res, Bethesda, MD 20014 USA
[2] NCI, Biostat & Data Management Sect, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[3] Correlog Syst Inc, Bethesda, MD USA
[4] Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Div Canc Med, Houston, TX 77030 USA
[5] Simone Protect Canc Inst, Lawrenceville, NJ USA
[6] Northwestern Univ, Sch Med, Natl Ovarian Canc Early Detect Program, Chicago, IL USA
关键词
D O I
10.1016/S0140-6736(02)07746-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background New technologies for the detection of early-stage ovarian cancer are urgently needed. Pathological changes within an organ might be reflected in proteomic patterns in serum. We developed a bioinformatics tool and used it to identify proteomic patterns in serum that distinguish neoplastic from non-neoplastic disease within the ovary. Methods Proteomic spectra were generated by mass spectroscopy (surface-enhanced laser desorption and ionisation). A preliminary "training" set of spectra derived from analysis of serum from 50 unaffected women and 50 patients with ovarian cancer were analysed by an iterative searching algorithm that identified a proteomic pattern that completely discriminated cancer from non-cancer. The discovered pattern was then used to classify an independent set of 116 masked serum samples: 50 from women with ovarian cancer, and 66 from unaffected women or those with non-malignant disorders. Findings The algorithm identified a cluster pattern that, in the training set, completely segregated cancer from non-cancer. The discriminatory pattern correctly identified all 50 ovarian cancer cases in the masked set, including all 18 stage I cases. Of the 66 cases of non-malignant disease, 63 were recognised as not cancer. This result yielded a sensitivity of 100% (95% CI 93-100), specificity of 95% (87-99), and positive predictive, value of 94% (84-99). Interpretation These findings justify a prospective population-based assessment of proteomic pattern technology as a screening tool for all stages of ovarian cancer in high-risk and general populations.
引用
收藏
页码:572 / 577
页数:6
相关论文
共 21 条
[1]   Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].
Alizadeh, AA ;
Eisen, MB ;
Davis, RE ;
Ma, C ;
Lossos, IS ;
Rosenwald, A ;
Boldrick, JG ;
Sabet, H ;
Tran, T ;
Yu, X ;
Powell, JI ;
Yang, LM ;
Marti, GE ;
Moore, T ;
Hudson, J ;
Lu, LS ;
Lewis, DB ;
Tibshirani, R ;
Sherlock, G ;
Chan, WC ;
Greiner, TC ;
Weisenburger, DD ;
Armitage, JO ;
Warnke, R ;
Levy, R ;
Wilson, W ;
Grever, MR ;
Byrd, JC ;
Botstein, D ;
Brown, PO ;
Staudt, LM .
NATURE, 2000, 403 (6769) :503-511
[2]  
[Anonymous], NONPARAMETRIC STAT M
[3]   TESTS FOR LINEAR TRENDS IN PROPORTIONS AND FREQUENCIES [J].
ARMITAGE, P .
BIOMETRICS, 1955, 11 (03) :375-386
[4]   A RADIOIMMUNOASSAY USING A MONOCLONAL-ANTIBODY TO MONITOR THE COURSE OF EPITHELIAL OVARIAN-CANCER [J].
BAST, RC ;
KLUG, TL ;
STJOHN, E ;
JENISON, E ;
NILOFF, JM ;
LAZARUS, H ;
BERKOWITZ, RS ;
LEAVITT, T ;
GRIFFITHS, CT ;
PARKER, L ;
ZURAWSKI, VR ;
KNAPP, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (15) :883-887
[5]   SOME METHODS FOR STRENGTHENING THE COMMON X2 TESTS [J].
COCHRAN, WG .
BIOMETRICS, 1954, 10 (04) :417-451
[6]   Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction [J].
Cohen, LS ;
Escobar, PF ;
Scharm, C ;
Glimco, B ;
Fishman, DA .
GYNECOLOGIC ONCOLOGY, 2001, 82 (01) :40-48
[7]   Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring [J].
Golub, TR ;
Slonim, DK ;
Tamayo, P ;
Huard, C ;
Gaasenbeek, M ;
Mesirov, JP ;
Coller, H ;
Loh, ML ;
Downing, JR ;
Caligiuri, MA ;
Bloomfield, CD ;
Lander, ES .
SCIENCE, 1999, 286 (5439) :531-537
[8]  
Herbert B.R., 1997, PROTEOME RES NEW FRO, P13
[9]  
HOLLAND JH, 1994, ADAPTATION NATURAL A
[10]   Screening for ovarian cancer: a pilot randomised controlled trial [J].
Jacobs, IJ ;
Skates, SJ ;
MacDonald, N ;
Menon, U ;
Rosenthal, AN ;
Davies, AP ;
Woolas, R ;
Jeyarajah, AR ;
Sibley, K ;
Lowe, DG ;
Oram, DH .
LANCET, 1999, 353 (9160) :1207-1210